^
    TNFRSF8 positive
    HL
    brentuximab vedotin
    Sensitive: A1 - Approval
    No biomarker
    HL
    pembrolizumab
    Sensitive: A1 - Approval
    No biomarker
    HL
    carmustine
    Sensitive: A1 - Approval
    No biomarker
    HL
    brentuximab vedotin
    Sensitive: A1 - Approval
    No biomarker
    HL
    nivolumab
    Sensitive: A1 - Approval
    No biomarker
    HL
    penpulimab
    Sensitive: A1 - Approval
    No biomarker
    HL
    AB122
    Sensitive: A1 - Approval
    No biomarker
    HL
    R-CHOP
    Sensitive: A2 - Guideline
    No biomarker
    HL
    rituximab
    Sensitive: A2 - Guideline
    No biomarker
    HL
    R-CVP
    Sensitive: A2 - Guideline
    No biomarker
    HL
    bortezomib
    Sensitive: A2 - Guideline
    No biomarker
    HL
    everolimus
    Sensitive: A2 - Guideline
    No biomarker
    HL
    carboplatin + etoposide oral + bendamustine
    Sensitive: A2 - Guideline
    No biomarker
    HL
    bendamustine
    Sensitive: A2 - Guideline
    No biomarker
    HL
    nivolumab + brentuximab vedotin
    Sensitive: A2 - Guideline
    No biomarker
    HL
    lenalidomide
    Sensitive: A2 - Guideline
    No biomarker
    HL
    GemOx
    Sensitive: A2 - Guideline
    No biomarker
    HL
    ICE
    Sensitive: A2 - Guideline
    No biomarker
    HL
    ESHAP
    Sensitive: A2 - Guideline
    No biomarker
    HL
    DHAP
    Sensitive: A2 - Guideline
    No biomarker
    HL
    R-ESHAP
    Sensitive: A2 - Guideline
    No biomarker
    HL
    MINE
    Sensitive: A2 - Guideline
    No biomarker
    HL
    BEACOPP
    Sensitive: A2 - Guideline
    TNFRSF8 positive
    HL
    AFM13
    Sensitive: C2 – Inclusion Criteria
    CHD8 mutation
    HL
    sintilimab
    Resistant: C3 – Early Trials
    CELF2 mutation
    HL
    sintilimab
    Resistant: C3 – Early Trials
    ABCC2 underexpression
    HL
    nivolumab + brentuximab vedotin
    Sensitive: C3 – Early Trials
    PD-1 underexpression
    HL
    nivolumab + brentuximab vedotin
    Sensitive: C3 – Early Trials
    CD163 overexpression
    HL
    nivolumab + brentuximab vedotin
    Sensitive: C3 – Early Trials
    CD14 overexpression
    HL
    nivolumab + brentuximab vedotin
    Sensitive: C3 – Early Trials
    TNFRSF8 positive
    HL
    TT11
    Sensitive: C3 – Early Trials
    TNFRSF14 mutation
    HL
    sintilimab
    Resistant: C3 – Early Trials
    MHC-II expression
    HL
    nivolumab
    Sensitive: C3 – Early Trials
    CASP3 underexpression + BCL2 positive
    HL
    ABVD
    Resistant: C3 – Early Trials
    CASP3 overexpression
    HL
    ABVD
    Sensitive: C3 – Early Trials
    BCL2 expression
    HL
    ABVD
    Resistant: C3 – Early Trials
    CASP3 overexpression + BCL2 negative
    HL
    ABVD
    Sensitive: C3 – Early Trials
    B2M mutation
    HL
    sintilimab
    Resistant: C3 – Early Trials
    TNFRSF8 overexpression
    HL
    nivolumab + brentuximab vedotin
    Sensitive: C3 – Early Trials
    Chr amplification(9)(p24.1)
    HL
    nivolumab
    Sensitive: C3 – Early Trials
    BCL2 overexpression
    HL
    venetoclax
    Resistant: D – Preclinical
    CD123 positive
    HL
    VIP943
    Sensitive: D – Preclinical
    BCL2 expression
    HL
    venetoclax
    Sensitive: D – Preclinical
    XPO1 E571K
    HL
    venetoclax + selinexor
    Sensitive: D – Preclinical
    XPO1 E571K
    HL
    venetoclax
    Sensitive: D – Preclinical